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Summary
OBJECTIVE: Coronary artery bypass grafting (CABG) re-
mains the gold standard for complex revascularisation in
multivessel disease. The concept of the minimally invasive
extracorporeal circulation circuit (MiECC) was introduced
to minimise pathophysiological side effects of convention-
al extracorporeal circulation. This study presents early and
long-term outcomes after CABG with use of MiECC in a
single-centre consecutive patient cohort.
METHODS: From 1 January 2005 to 31 December 2010,
2130 patients underwent isolated CABG with MiECC at
our centre. We evaluated morbidity and mortality follow-
up data with a median follow-up of 3.6 years. Kaplan-
Meier curves and estimates of the primary end-point for
all-cause mortality were compared with the life expectancy
of the general population.
RESULTS: Mortality in CABG patients was comparable
to the general population beginning 1 year after surgery
for the whole observation period. All-cause 30-day mor-
tality was 0.8%. The mean estimated logistic EuroSCORE
and EuroSCORE II were 5.8 ± 8.6 and 3.0 ± 5.1, respec-
tively. Mean perfusion time was 71.1 ± 23.8 min with a
cross-clamp time of 44.9 ± 16.3 min. Mortality was predict-
ed by the presence of diabetes mellitus (odds ratio [OR]
1.85, 95% confidence interval [CI] 1.40–2.46; p <0.001),
peripheral arterial disease (OR 2.36, 95% CI 1.64–3.38; p
<0.001), severe obstructive pulmonary disease (OR 3.21,
1.42–7.24; p = 0.005), chronic renal failure (OR 3.68,
2.49–5.43; p <0.001) and transfusion of more than one
unit of erythrocyte concentrate in the perioperative period
(OR 1.46, 1.09–1.95; p = 0.015). Cerebrovascular events
occurred in 36 patients (1.7%).
CONCLUSION: CABG with use of MiECC is associated
with a mortality rate comparable to the overall life ex-
pectancy of the general population. MiECC is the first
choice for routine and emergency CABG at our centre with
a 30-day mortality rate of 0.8% and a low complication
rate.
Key words: minimal invasive extracorporeal circulation
technologies, coronary artery bypass grafting, life ex-
pectancy
Introduction
Coronary artery bypass grafting (CABG) represents the
optimal revascularisation strategy for complex coronary
artery disease. This treatment strategy is followed by ex-
cellent long-term survival with a lower rate of re-interven-
tions compared with percutaneous interventions, a similar
rate of major adverse cardiac and cerebrovascular events
(MACCE) and, for the majority of the patients, some clear
clinical and economic advantages [1, 2].
The optimal operating environment is facilitated by car-
diopulmonary bypass (CPB) with arrested heart and blood-
less operating field, which allows the most complete revas-
cularisation even in the presence of very complex anatomy.
Drawbacks of this technology include the triggering of
a systemic inflammatory response due to the contact of
blood with the foreign surfaces, as well as the requirement
for priming fluid, which may result in a significant post-
operative morbidity. Off-pump coronary artery bypass was
one of the few answers to these problems, but was never
generally accepted in the cardio-surgical community be-
cause of some intraoperative challenges, such as refractory
hypotension during manipulations on the heart. Large stud-
ies and meta-analyses have not been able to demonstrate
a significant benefit of off-pump surgery, but a higher rate
of incomplete revascularisation leading to a more frequent
rate of re-intervention was observed [3, 4].
The concept of the minimally invasive extracorporeal cir-
culation circuit (MiECC) was introduced to combine the
advantages and eliminate disadvantages of both strategies
(conventional CPB and off-pump). The standard minimal
invasive extracorporeal circuit consists of a centrifugal
pump with a membrane oxygen exchanger; short heparin-
coated tubing with biologically inert surfaces, heat ex-
changer, venous de-airing components and shed-blood
management system [5, 6]. Developments in this field
throughout the last 10 years, as well as growing experience
with its use, allowed publication of the first guidelines on
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usage of MiECC for closed and open cardiac surgery ear-
lier this year [5]. Despite known advantages, the percent-
age of coronary bypass operations performed with MiECC
compared with standard CPB still remains limited [5]. At
our institution, we introduced MiECC as early as 2000
and MiECC has been the standard extracorporeal circu-
lation strategy for isolated CABG since 2005. This study
summarises the experience of over two thousand opera-
tions performed in the first 5 years after implementation of
MiECC at our centre, with a report on mortality and mor-
bidity during the follow-up period in comparison with the
life expectancy of the general population of Switzerland.
Materials and methods
Patient population
Between 1 January 2005 and 31 December 2010, 2130 pa-
tients underwent isolated, elective or emergent CABG with
use of MiECC in our institution and were included in the
present analysis (fig. 1). To avoid confounding factors, we
excluded patients who required any concomitant cardiac or
vascular procedures (for instance, carotid endarterectomy,
valve surgery, etc.). Patients, or their relatives in the event
of emergency, signed, on the day of admission to the hospi-
tal and prior to surgery, general informed consent for data
collection and regular follow-up for the purpose of medical
research. In this study a retrospective observational design
was used, conforming to the STROBE checklist [7].
Operational technique and perioperative management
The typical minimally invasive cardiopulmonary circuit
consists of a closed circuit, which includes the oxygenator
and the pump. The circuit has no open venous reservoir
like a conventional extracorporeal circulation circuit
Figure 1: Patient selection.CABG = coronary artery bypass graft;
ECC = extracorporeal circulation; OPCAB = off-pump coronary
artery bypassFrom: Moher D, Liberati A, Tetzlaff J, Altman DG;
PRISMA Group. Preferred reporting items for systematic reviews
and meta-analyses: the PRISMA statement. PLoS Med. 2009 Jul
21;6(7):e1000097. doi: 10.1371/journal.pmed.1000097.
(ECC). All components of the MiECC are coated with
heparin and the tubing system is significantly reduced in
length when compared with the ECC. These characteristics
permit a reduction of the priming volume from 1800 to
600–400 ml compared with the standard ECC and, further-
more, reduce negative side effects [3, 8, 9].
The MiECC of Maquet® (Cardiopulmonary AG, Hirrlin-
gen, Germany) with the RotaFlow® centrifugal pump
(RotaFlow, Jostra AG) with hydrophobic oxygenation
membrane (Quadrox Safeline®, Maquet, Cardiopul-
monary AG, Hirrlingen, Germany) were used at that time
for the extracorporeal perfusion circuit. The priming vol-
ume of this system was 600 ml compared 1800 ml in stan-
dard CPB. Single shot (100 ml) crystalloid cardioplegia,
as described elsewhere, was used [10]. The perfusion flow
during MiECC was set to 2 litres per square meter of body
surface area and, if needed, optimised by the perfusion-
ist. Unfractionated heparin (200–300 units/kilogram body
weight) was administered per institutional protocol as ini-
tial bolus to all patients and tailored to the target of ac-
tivated clotting time of at least 480 seconds (ACT plus®,
Medtronic©).
Data collection
Preoperative data (including gender, age, comorbidities,
medication on admission, functional New York Heart As-
sociation class (NYHA), Canadian Cardiovascular Society
(CCS) score, prior myocardial infarction, systolic left ven-
tricular ejection fraction (LVEF) and perioperative risk (as-
sessed according to the logistic EUROSCORE, additive
EUROSCORE and EUROSCORE II), intraoperative data
(including the number of grafted vessels, perfusion and
cross-clamping time), as well as early postoperative data,
were prospectively collected for the purpose of quality
management at our institution (table 1).
For each patient, we calculated the additive and the logistic
EuroSCORE, as well as the EuroSCORE II, which predict
the risk of 30-day all-cause mortality from preoperative
factors based on a logistic regression model using age, sex,
comorbid conditions, patient history and LVEF. The addi-
tive EuroSCORE ranges from 0 to about ≥40 (as age scores
linearly per 5 years increment, the score is not strictly lim-
ited), the logistic EuroSCORE and EuroSCORE II range
from 0.88 or 0.5, respectively, to <100, representing the
risk of perioperative death in % [11–13].
The follow-up data were obtained directly through ambula-
tory FU or telephone interview with the patient or the gen-
eral practitioner.
Herewith we documented the presence and severity of dys-
pnoea, angina pectoris, major cardiovascular events after
the operation (myocardial infarction, cerebrovascular
event, cardiovascular death, repeated revascularisation),
death from any cause.
Statistical analysis
All consecutive patients undergoing surgery were included
in the analysis. Missing data were not included in the final
statistics (accounting for less than 10% of the patients lost
for the long-term follow up). Continuous data are present-
ed as mean ± standard deviation (SD) and categorical vari-
ables are displayed as frequency distributions (n) and sim-
ple percentages (%).
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Kaplan-Meier estimates of cumulative probabilities were
calculated for the primary endpoint of death for the pa-
tients operated on. We used published data about life ex-
pectancy in Switzerland, stratified for gender and year of
birth, to match a corresponding record from the general co-
hort to each patient in the study cohort. Furthermore, the
Kaplan-Meier estimates were stratified by quintiles of the
logistic EuroSCORE for the whole population and by gen-
der.
Logistic regression analysis was performed for early mor-
tality, as well as for the adverse events such as periop-
erative myocardial infarction, cerebrovascular event and
emergent reoperation.
Poisson regression was used to analyse skewed continuous
variables such as length of hospital stay. Long term mortal-
ity was investigated using Cox proportional hazard regres-




Out of 6308 patients operated on from 2005 to 2010, 2130
underwent isolated CABG with MiECC (33.7%) and were
included in the current analysis (fig. 1). Overall, 445 pa-
tients (20.9%) were female, and the mean age was 65.8
years (±9.8 years). Dyspnoea in NYHA functional classes
III and IV was reported in 403 patients (19%). Prior my-
ocardial infarction occurred in 33 patients (2%) 6 hours be-
fore surgery, in 139 patients (7%) 24 hours earlier and in
463 patients (23%) 7 days before surgery (table 1).
Percutaneous revascularisation was attempted in 387 of
those patients (18%). The estimated LVEF was normal
with the mean of 54.9% (±12.9%). The estimated operative
risks calculated with the standard and logistic EuroSCORE
and EuroSCORE II were 4.6 (±3.3), 5.8 (±8.6) and 3.0
(±5.1), respectively.
Operative data
An arterial graft was the preferred option for revascularisa-
tion of the left anterior descending artery with a second ar-
terial graft for the circumflex branch when appropriate and
feasible, with a mean of 1.3 (±0.8) arterial and 2.0 (±1.1)
venous grafts (table 2). The detailed choice of grafts is pre-
sented in table 3. The mean perfusion time was 71.1 min-
utes (±23.8 minutes) and the mean cross-clamp time 44.9
minutes (±16.3 minutes) (table 2).
Outcome and survival prediction scores
All-cause mortality was 0.8% at 30 days (table 3) and 9.1%
at 6 years, comparable to the expected survival of the gen-
der- and age-matched general Swiss population (fig. 2). In-
dependent risk factors according to the logistic regression
analysis for 30-day mortality were LVEF of less than 30%
with the odds ratio (OR) of 5.03 (95% confidence interval
[CI] 1.43–17.74; p = 0.012) and diabetes mellitus with OR
3.64 (95% CI 1.40–9.43; p = 0.008), whereas elective oper-
Table 1: Baseline characteristics of the Bern cohort.
Grouped by logistic EuroSCOREAll patients(n =
2130) Quintile 1(n =
433)
Quintile 2(n = 425) Quintile 3(n =
430)
Quintile 4(n = 419) Quintile 5(n = 423) p-value
Age 65.8 (±9.8) 56.8 (±6.7) 62.8 (±7.7) 68.3 (±8.2) 70.2 (±8.6) 71.0 (±9.6) 0.00
Female gender 445 (20.9%) 26 (6.0%) 64 (15.1%) 97 (22.6%) 114 (27.2%) 144 (34.0%) 0.00
BMI 27.5 (±4.4) 28.2 (±4.4) 27.7 (±4.2) 27.3 (±4.4) 27.1 (±4.2) 27.2 (±4.7) 0.02
Diabetes 649 (30.5%) 120 (27.7%) 125 (29.4%) 137 (31.9%) 116 (27.7%) 151 (35.7%) 0.05
Hypertension 1688 (79.2%) 328 (75.8%) 338 (79.5%) 342 (79.5%) 339 (80.9%) 341 (80.6%) 0.35
Hyperlipidaemia 1641 (77.0%) 351 (81.1%) 338 (79.5%) 319 (74.2%) 318 (75.9%) 315 (74.5%) 0.05
Smoking 1269 (59.6%) 297 (68.6%) 273 (64.2%) 253 (58.8%) 237 (56.6%) 209 (49.4%) 0.00
Previous cerebrovascular event 126 (5.9%) 10 (2.3%) 20 (4.7%) 24 (5.6%) 37 (8.8%) 35 (8.3%) 0.00
Arteriopathy 356 (16.7%) 0 (0.0%) 41 (9.6%) 61 (14.2%) 104 (24.8%) 150 (35.5%) 0.00
Renal dysfunction* 123 (5.8%) 6 (1.4%) 18 (4.2%) 21 (4.9%) 34 (8.1%) 44 (10.4%) 0.00
Most recent MI 0.00
<6 hours 33 (1.5%) 0 (0.0%) 1 (0.2%) 0 (0.0%) 1 (0.2%) 31 (7.3%)
6–24 hours 104 (4.9%) 0 (0.0%) 4 (0.9%) 7 (1.6%) 18 (4.3%) 75 (17.7%)
1–7 days 356 (16.7%) 1 (0.2%) 48 (11.3%) 60 (14.0%) 115 (27.4%) 132 (31.2%)
8–21 days 131 (6.2%) 6 (1.4%) 21 (4.9%) 22 (5.1%) 39 (9.3%) 43 (10.2%)
22–90 days 96 (4.5%) 1 (0.2%) 24 (5.6%) 19 (4.4%) 29 (6.9%) 23 (5.4%)
>90 days 275 (12.9%) 80 (18.5%) 57 (13.4%) 55 (12.8%) 45 (10.7%) 38 (9.0%)
No MI 1135 (53.3%) 345 (79.7%) 270 (63.5%) 267 (62.1%) 172 (41.1%) 81 (19.1%)
Previous PCI 388 (18.2%) 84 (19.4%) 92 (21.6%) 70 (16.3%) 71 (16.9%) 71 (16.8%) 0.21
NYHA class 0.00
I 854 (40.1%) 213 (49.2%) 206 (48.5%) 164 (38.1%) 153 (36.5%) 118 (27.9%)
II 870 (40.8%) 178 (41.1%) 175 (41.2%) 193 (44.9%) 177 (42.2%) 147 (34.8%)
III 301 (14.1%) 37 (8.5%) 37 (8.7%) 64 (14.9%) 73 (17.4%) 90 (21.3%)
IV 105 (4.9%) 5 (1.2%) 7 (1.6%) 9 (2.1%) 16 (3.8%) 68 (16.1%)
LVEF 54.8 (±13.0) 60.6 (±9.3) 58.9 (±10.2) 56.8 (±11.5) 52.1 (±13.2) 45.7 (±14.5) 0.00
Additive EuroSCORE 4.6 (±3.3) 0.7 (±0.7) 2.6 (±0.5) 4.2 (±0.6) 5.9 (±0.8) 9.7 (±2.5) 0.00
Logistic EuroSCORE 5.8 (±8.6) 1.1 (±0.2) 1.9 (±0.3) 3.1 (±0.5) 5.3 (±1.0) 17.9 (±13.3) 0.00
EuroSCORE II 3.0 (±5.1) 0.8 (±0.3) 1.2 (±0.5) 1.7 (±0.8) 2.7 (±1.6) 8.6 (±9.2) 0.01
BMI = body mass index; LVEF = left ventricular ejection fraction; MI = myocardial infarction; NYHA = New York Heart Association; PCI = percutaneous coronary intervention. *
last preoperative creatinine > 200 μmol/l or dialysis
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ation was protective compared with emergency procedures
in this context, with an OR of 0.26 (95% CI 0.10-0.69; p =
0.015).
Perioperative myocardial infarction (table 3) occurred in
42 patients (2%). Independent predictors for myocardial
infarction were peripheral arterial disease (OR 3.76, 95%
Figure 2: Kaplan-Meier curve representing 6-year life expectancy
of the patient cohort in comparison with the general population of
Switzerland.CI = confidence interval
CI 1.86–7.61; p <0.001), chronic renal failure (OR 3.38,
95% CI 1.47–7.78; p = 0.004), need of perioperative ery-
throcyte transfusion (OR 2.00, 95% CI 1.08–3.70); elective
operation (OR 0.47, 95% CI 0.25–0.86; p = 0.027) repre-
sented a protective factor against postoperative morbidity.
Cerebrovascular events occurred in 36 patients (1.7%) and
were more frequent in the presence of the peripheral arte-
rial disease with OR 2.99 (95% CI 1.34–6.65; p = 0.007),
severe obstructive pulmonary disease (OR 6.93, 95% CI
2.00–23.98; p = 0.002) and chronic renal failure (OR 3.39,
95% CI 1.39–8.32; p = 0.008). Further perioperative find-
ings, as well as the discharge details including length of
stay are shown in table 3.
Long term mortality was predicted by the presence of di-
abetes mellitus with an OR of 1.85 (95% CI 1.40–2.46;
p <0.001), peripheral arterial disease (OR 2.36, 95% CI
1.64–3.38; p <0.001), severe obstructive pulmonary dis-
ease (OR 3.21, 95% CI 1.42–7.24; p = 0.005), chronic re-
nal failure (OR 3.68, 95% CI 2.49–5.43; p <0.001) and
transfusion of more than one unit of erythrocyte concen-
trate in the perioperative period (OR 1.46, 95% CI
1.09–1.95; p = 0.015).
Table 2: Operative data.
Logistic EuroSCOREAll patients(n =











No. of arterial anastomoses 1.3 (±0.8) 1.7 (±0.9) 1.5 (±0.8) 1.2 (±0.6) 1.2 (±0.6) 1.1 (±0.7) <0.001
LIMA 2062 (96.8%) 422 (97.5%) 422 (99.3%) 419 (97.4%) 410 (97.9%) 389 (92.0%) <0.001
Radial 365 (17.1%) 139 (32.1%) 94 (22.1%) 50 (11.6%) 38 (9.1%) 44 (10.4%) <0.001
RIMA 200 (9.4%) 99 (22.9%) 53 (12.5%) 14 (3.3%) 15 (3.6%) 19 (4.5%) <0.001
Arterial grafts only 222 (10.4%) 92 (21.2%) 50 (11.8%) 30 (7.0%) 23 (5.5%) 27 (6.4%) <0.001
No. of venous anastomoses 2.0 (±1.1) 1.5 (±1.1) 1.9 (±1.1) 2.1 (±1.0) 2.3 (±1.0) 2.2 (±1.0) <0.001
No. of grafts 3.3 (±0.9) 3.2 (±0.9) 3.3 (±0.9) 3.3 (±0.9) 3.4 (±0.9) 3.3 (±0.9) 0.091
Perfusion time (min) 71.2 (±24.0) 68.4 (±23.2) 70.6 (±25.4) 71.1 (±22.3) 72.6 (±22.1) 73.2 (±26.6) 0.21
Cross-clamp time (min) 44.9 (±16.3) 44.5 (±16.5) 45.3 (±17.2) 44.5 (±16.3) 45.8 (±15.3) 44.5 (±16.3) 0.69
LIMA = left internal mammary artery; RIMA = right internal mammary artery
Table 3: Initial postoperative outcome risks by the logistic EuroSCORE.












Troponin T (ng/ml)* 0.8 (±2.0) 0.3 (±0.5) 0.6 (±1.5) 0.5 (±0.8) 0.7 (±1.1) 1.9 (±3.8) 0.22
Peak CK-MB (U/l) 27.2 (±47) 17.9 (±23) 25.0 (±41) 21.9 (±25) 29.0 (±60) 42.5 (±65) 0.08
Peak CK (U/l) 815 (±1147) 796 (±1105) 867 (±1090) 726 (±895) 753 (±1513) 935 (±1039) 0.20
Perioperative MI 42 (2.0%) 3 (0.7%) 9 (2.1%) 10 (2.3%) 8 (1.9%) 12 (2.8%) 0.22
New atrial fibrillation 335 (15.7%) 40 (9.2%) 51 (12.0%) 67 (15.6%) 70 (16.7%) 107 (25.3%) 0.00
Arrythmia† 45 (2.1%) 7 (1.6%) 4 (0.9%) 8 (1.9%) 7 (1.7%) 19 (4.5%) 0.00
Permanent pacemaker 9 (0.4%) 0 (0.0%) 0 (0.0%) 4 (0.9%) 0 (0.0%) 5 (1.2%) 0.01
Resuscitation 15 (0.7%) 0 (0.0%) 0 (0.0%) 1 (0.2%) 5 (1.2%) 9 (2.1%) 0.00
Reoperation on the sternum 22 (1.0%) 1 (0.2%) 3 (0.7%) 4 (0.9%) 7 (1.7%) 7 (1.7%) 0.17
Pericardial effusion/tamponade‡ 31 (1.5%) 5 (1.2%) 4 (0.9%) 7 (1.6%) 5 (1.2%) 10 (2.4%) 0.43
Cerebrovascular event 36 (1.7%) 1 (0.2%) 4 (0.9%) 6 (1.4%) 13 (3.1%) 12 (2.8%) 0.00
Renal dysfunction 0.00
Without dialysis 133 (6.2%) 9 (2.1%) 22 (5.2%) 30 (7.0%) 30 (7.2%) 42 (9.9%)
With dialysis 46 (2.2%) 3 (0.7%) 5 (1.2%) 8 (1.9%) 11 (2.6%) 19 (4.5%)
Pulmonary complication 129 (6.1%) 14 (3.2%) 19 (4.5%) 27 (6.3%) 25 (6.0%) 44 (10.4%) 0.00
ICU stay (days) 1.6 (±2.7) 1.2 (±1.0) 1.2 (±1.1) 1.4 (±1.5) 1.8 (±2.6) 2.6 (±4.8) 0.57
IMC stay (days) 1.2 (±2.7) 0.6 (±0.8) 0.8 (±1.2) 1.2 (±4.2) 1.4 (±2.3) 1.9 (±3.2) 0.00
Length of stay (days) 8.9 (±8.5) 6.9 (±3.3) 7.7 (±4.1) 8.9 (±12.4) 9.9 (±9.7) 11.0 (±8.7) 0.00
30-day mortality 18 (0.8%) 1 (0.2%) 3 (0.7%) 2 (0.5%) 4 (1.0%) 8 (1.9%) 0.07
CK-MB = creatine kinase muscle brain; CK = creatine kinase; ICU= intensive care unit; IMC = intermediate care; MI = myocardial infarction * patients with troponin I measurement
instead of troponin T are not displayed; † requiring intervention; ‡ requiring surgical treatment.
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The logistic EuroSCORE predicts survival in the cohort of
patients with minimised extracorporeal circulatory support
during the procedure (fig. 3). However, compared with the
actual observed mortality, the estimates of the logistic Eu-
roSCORE remain grossly overestimated, especially in the
late postoperative period, in both genders.
Discussion
The concept and strategy of MiECC was introduced to
reduce the disadvantages of standard extracorporeal cir-
culation. Several studies have already shown the benefits
of MiECC, including low mortality, less myocardial dam-
age, improved end-organ protection and easy application in
clinical practice [3, 14]. Several meta-analyses have sup-
ported these superior results of MiECC when compared
with standard extracorporeal circulation [3, 15]. Further-
more, a recent analysis has shown that MiECC does not
give inferior results in comparison with off-pump coronary
artery bypass.[16]. However, long-term follow-up data and
large cohort studies are needed to confirm these advan-
tages of MiECC over time.
This study presents early and long-term outcomes after
CABG with MiECC in a single-centre sequential patient
cohort. Long-term outcome after CABG with MiECC was
compared with the life expectancy of the general Swiss
population. CABG performed with use of an MiECC sys-
tem for intraoperative perfusion was associated with very
low early and late postoperative mortality for up to 6 years.
The overall 30-day mortality after CABG with MiECC
was 0.8%. Late mortality was comparable to the mortality
of the country’s general population matched for age and
gender. From year one after surgery the mortality rate in
the patient collective was comparable to the mortality rate
of the Swiss general population matched individually for
year of birth and gender. The general Swiss population
was chosen as the reference group for the study because
of Switzerland has a high living standard and the second
longest life expectancy in the world (83.4 years for both
sexes) [17].
In line with contemporary publications, we attribute the
low rate of early mortality and perioperative complications
to an attenuated inflammatory reaction and complement
activation response because of the reduced inert surfaces of
the closed extracorporeal circulation system. In addition,
the reduction of priming volume and minimised haemodi-
Figure 3: Stratification by quintiles of the logistic EuroSCORE dis-
tinguishes groups with respect to the risk of long-term mortality.
lution can influence the onset of anticoagulation disorders
[18, 19]. As a result, multiple publications have confirmed
lower intraoperative haemolysis and a lower risk of bleed-
ing, which is most pronounced among adults with a small
body surface area, paediatric patients and in the setting of
preoperative anaemia [20, 21].
On the other hand, higher mean arterial pressures during
perfusion with an MiECC circuit as compared with CPB,
and the reduced vasoactive support needed with much
more preserved physiological circulation and continuous
coronary flow, result in better end-organ perfusion [22,
23]. In clinical practice, this translates into superior my-
ocardial protection and reperfusion, with significantly re-
duced levels of cardiac injury markers, lower incidence of
postoperative atrial fibrillation, lower incidence of stroke,
less haemodialysis and lower creatinine levels postopera-
tively, and better neurocognitive and lung function [5, 18,
19, 24–27].
Apart from the endpoints mentioned above, MiECC of-
fered improvement of early mortality in a large meta-
analysis of 2770 patients [15]. This remained true for all
age groups, as well as for emergency and elective oper-
ations [28, 29]. The subjectively perceived quality of life
among patients was higher in the physical and mental sum-
mary scores, compared with that observed after conven-
tional CPB [30]. MiECC proved favourable for a fast-track
strategy (defined as minimal administration of opioids,
operation under normothermia, early postoperative extu-
bation and admission to the cardiosurgical ward within
24 hours after the operation with facilitation of early re-
covery) with an OR of success of 3.8 in the randomised
study by Anastasiadis et al. [31]. Surprisingly despite very
promising results in larger cohorts, the penetration of
MiECC remains low. Concerns about de-airing of the sys-
tem were initially raised and addressed in one small ran-
domised trial, which showed higher rates of cerebral
gaseous emboli after aortic valve replacement with MiECC
compared with standard CPB, without significant differ-
ence in the clinical outcome [32]. However, the results of
Basciani et al. remain in contradiction to existing larger ob-
servational trials in which de-airing modules were imple-
mented in the MiECC [27, 33].
An analysis of cost effectiveness in various European
countries showed a cost reduction of EUR 635 in Greece,
EUR 297 in Germany, EUR 1590 in the Netherlands and
EUR 375 in Switzerland for the MiECC system. In the
same article there was a strong tendency towards more life
years gained with the minimally invasive technology [34].
The risk of mortality and perioperative complications is
augmented in the presence of several risk factors included
in contemporary preoperative risk estimation scores. The
anticipated mortality was significantly lower in the real life
cohort. These results remained in line with the recent pub-
lication of Koivisto et al. [35]. Similar findings have been
shown for patients undergoing CABG with traditional CPB
[36]. We therefore believe that further research is needed
to optimise the risk stratification in patients operated with
MiECC support, especially with the expanding indications
of coronary artery stenting. In many cases, minimally inva-
sive, fast-track operation offers an interesting alternative,
especially in the patients with higher operative risk.
We acknowledge some limitations of our study. It was
a retrospective observational analysis and therefore cause
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and effect are hard to establish. Best evidence would be
guaranteed by performing a prospective randomised con-
trolled multicentre study. Another limitation may be that
in cases where the decision to use MiECC is left at the
discretion of the treating physician, selection bias might
occur. However, the patient characteristics are similar to
those reported in randomised studies, and therefore we
consider selection bias unlikely. Another shortcoming is
the fact that the intervention group was matched against
the same age general population and not the population op-
erated with standard of care, namely with conventional car-
diopulmonary bypass. The concept of MiECC has already
been proved by other research groups and thus we decid-
ed to compare the outcome after CABG against the life ex-
pectancy of the general population to highlight the good
performance of the approach at our institution.
Conclusion
MiECC shows very promising results in our patient cohort,
inclusively when the long term follow up is concerned,
since the latter is comparable to that of an age and gender
matched general population. We thus believe that MiECC
should be used in every case of on-pump CABG, when
technically feasible.
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